Home

Conference Correspondent™ provides on-site daily coverage of key sessions at particular scientific meetings. Conference Correspondent™ takes healthcare providers to meetings they cannot attend live, and your sponsorship helps create awareness for your brand or therapeutic area.

View All Conference Highlights

NSCLC IO 2022 Midyear Review

Circulating Tumor DNA–Guided Therapy of Advanced NSCLC with Immune Checkpoint Inhibitor–Based Regimens

NSCLC IO 2022 - Midyear Review – June 16, 2022

NSCLC IO 2022 - Midyear Review

Lung Cancer Treatment Selection Based on a Multiplexed Proteomic Assay

NSCLC IO 2022 - Midyear Review – June 16, 2022

NSCLC IO 2022 - Midyear Review

Machine Learning–Based Integration of Radiology, Pathology, and Genomics to Predict Response to PD-1 Inhibition in Patients with NSCLC

NSCLC IO 2022 - Midyear Review – June 16, 2022

NSCLC IO 2022 - Midyear Review

Investigation of Acquired Resistance Biomarkers to Anti–PD-(L)1 Therapy in Patients with Advanced NSCLC

NSCLC IO 2022 - Midyear Review – June 16, 2022

NSCLC IO 2022 - Midyear Review

Time-Dependent Efficacy of Nivolumab in Patients with Advanced NSCLC

NSCLC IO 2022 - Midyear Review – June 16, 2022

NSCLC IO 2022 - Midyear Review

VIEW FULL COVERAGE

ASCO 2022 – Wrap Up

DESTINY-Breast04 Compared T-DXd with TPC in Patients with HER2-Low Breast Cancer

ASCO 2022 – Wrap-Up – June 14, 2022

American Society of Clinical Oncology (ASCO)

TROPiCS-02 Primary Results: Sacituzumab Govitecan versus Treatment of Physician’s Choice in Patients with Advanced Breast Cancer

ASCO 2022 – Wrap-Up – June 14, 2022

American Society of Clinical Oncology (ASCO)

Ribociclib Efficacious in Patients with Unresectable or HR-Positive/HER2-Negative Metastatic Breast Cancer Receiving Fulvestrant or Exemestane After Not Responding to Prior Treatments

ASCO 2022 – Wrap-Up – June 14, 2022

American Society of Clinical Oncology (ASCO)

Event-Free Survival by Residual Cancer Burden After Neoadjuvant Chemotherapy + Pembrolizumab for Early TNBC: KEYNOTE-522 Data

ASCO 2022 – Wrap-Up – June 14, 2022

American Society of Clinical Oncology (ASCO)

Revised Overall Survival and Progression-Free Survival Data from the FAKTION Study: Capivasertib + Fulvestrant in Metastatic, ER-Positive Breast Cancer

ASCO 2022 – Wrap-Up – June 14, 2022

American Society of Clinical Oncology (ASCO)

VIEW FULL COVERAGE

Dual IO 2021 Year in Review

Phase 2 Study of Nivolumab plus Ipilimumab in Metastatic Uveal Melanoma

Dual IO 2021 - Year in Review – March 7, 2022

Dual IO 2021 - Year in Review

Phase 2 Trial of Nivolumab plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: Spanish Multidisciplinary Melanoma Group (GEM-1402)

Dual IO 2021 - Year in Review – March 7, 2022

Dual IO 2021 - Year in Review

Benefits of Dual I-O Therapy in Metastatic Uveal Melanoma

By Sanjiv S. Agarwala, MD

Dual IO 2021 - Year in Review – March 7, 2022

Dual IO 2021 - Year in Review

Relatlimab plus Nivolumab versus Nivolumab Alone in First-Line Advanced Melanoma: Primary Results from RELATIVITY-047

Dual IO 2021 - Year in Review – March 7, 2022

Dual IO 2021 - Year in Review

Nivolumab plus Ipilimumab as First-Line Therapy in Patients with Advanced Melanoma: 6.5-Year Update from CheckMate-067

Dual IO 2021 - Year in Review – March 7, 2022

Dual IO 2021 - Year in Review

VIEW FULL COVERAGE